Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: C$5.75 to C$5.75
• 50-Day Range: C$5.43 to C$6.27
• 52-Week Range: C$5.09 to C$6.45
• Volume: 1,150 shs
• Average Volume: 72,576 shs
• Market Capitalization: C$581.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.48
• Consensus Rating: Buy

GUD Stock Analysis - Frequently Asked Questions

How have GUD shares performed this year?

Knight Therapeutics' stock was trading at C$5.34 at the beginning of the year. Since then, GUD shares have increased by 7.5% and is now trading at C$5.74.
View the best growth stocks for 2025 here.

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$7.48
• High Stock Price Target: C$7.50
• Low Stock Price Target: C$7.45
• Potential Upside/Downside: +30.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 56.86
• P/E Growth: -1013.5
• Net Income: C$-30,734,242.45
• Net Margins: -8.81%
• Pretax Margin: N/A
• Return on Equity: -4.04%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 7.52
• Current Ratio: 3.36
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$348.70 million
• Price / Sales: 1.67
• Cash Flow: C$1.49 per share
• Price / Cash Flow: 3.85
• Book Value: C$7.65 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 101,150,053
• Free Float: N/A
• Market Cap: C$580.60 million
• Optionable: Not Optionable
• Beta: 0.50